Budapest-based biotech startup Turbine has raised funding from Accenture Ventures. This investment is intended to accelerate the use of Turbine's AI-powered cell simulations, which are used in biopharmaceutical research. The precise amount of the deal remains undisclosed.
- Established in 2016 by Dániel Veres, Kristóf Zsolt Szalay, and Szabolcs Nagy, Turbine specializes in the development of a Simulated CellTM platform. This platform employs machine learning to understand human cell decisions, thereby facilitating virtual experiments for unveiling hidden treatments and potential lab-tested drugs.
- Turbine forged partnerships with several firms, including Accel, Bayer, Ono, OZH Ventures, Delin Ventures, day1 Capital, XTX Ventures, and Mercia.
Details of the deal
- The investment was made by Accenture Ventures managed by leading global services company Accenture, through an investment program focusing on disruptive enterprise technologies, providing access to Accenture's expertise and enterprise clients.
“By tapping into Accenture’s expertise, we hope to expand our market reach and augment our simulation platform in order to benefit the whole biopharma industry by ensuring that the next experiment is always the correct one,” Co-founder and CEO of Turbine, Szabolcs Nagy, commented.
- The fresh investment will enhance Turbines Capabilities for global biopharma companies, enabling the uncovering of biological insights and acceleration of key drug development workstreams.
